A Phase I/II, Open-label, Dose Escalation and Extension Study of Intravesical Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Latest Information Update: 30 May 2025
At a glance
- Drugs Eciskafusp alfa (Primary)
- Indications Bladder cancer; Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
Most Recent Events
- 23 May 2025 Planned initiation date changed from 15 May 2025 to 15 Jun 2025.
- 27 Apr 2025 Planned initiation date changed from 31 Mar 2025 to 15 May 2025.
- 01 Apr 2025 Status changed from not yet recruiting to recruiting.